Parexel management changes
Executive Summary
Parexel COO Carl Spalding will retire effective June 30; the COO position will remain unfilled for the foreseeable future, the contract research organization said. President-Clinical Research Services Michael Woehler is promoted to Exec VP, and President-Perceptive Informatics Mark Goldberg will take Woehler's former title; Goldberg will also continue to oversee perceptive informatics. Kurt Brykman is promoted to president-consulting and medical marketing services...
You may also be interested in...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: